Sclerostin: a key regulator of bone mineralisation and bone catabolism

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1004871

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

The regulation of bone mass is critical for many areas of human disease including osteoporosis, osteoarthritis, inflammatory bone loss conditions, e.g. rheumatoid arthritis, cancers of bone and problems relating to orthopaedic prosthesis failure. The osteocyte, the most abundant bone cell, plays a central role in normal bone biology and is likely key to these diseases. Sclerostin is one osteocyte product that may be a key to understanding how boneÍs mass and composition is controlled locally.

Funded Activity Details

Start Date: 01-01-2011

End Date: 01-01-2013

Funding Scheme: Project Grants

Funding Amount: $536,653.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Medical and Health Sciences not elsewhere classified

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

bone biology | bone cells | bone metabolism | bone turnover | skeletal disease

Related Links